BRCA2 and uterine corpus sarcoma: Homozygous deletions of BRCA2 were present in 5% of uterine sarcoma patients in another study and evidence of clinical benefit in patients with uterine leiomyosarcoma with somatic BRCA2 alterations treated with PARP inhibitors has been described [52].